1. Home >
  2. M&A >
  3. PIPE >
  4. United States >
  5. Ampersand Capital Partners Invests In ANI Pharmaceuticals

Investment Summary

Ampersand Capital Partners Invests In ANI Pharmaceuticals

On March 8, 2021, growth capital firm Ampersand Capital Partners invested in life science company ANI Pharmaceuticals

Investment Highlights
  • This is Ampersand Capital Partners’ 28th transaction in the Life Science sector.
  • This is Ampersand Capital Partners’ 54th transaction in the United States.
  • This is Ampersand Capital Partners’ 3rd transaction in Minnesota.

Investment Summary
Date 2021-03-08
Target ANI Pharmaceuticals
Sector Life Science
Investor(s) Ampersand Capital Partners
Deal Type PIPE

Target

ANI Pharmaceuticals

Baudette, Minnesota, United States
ANI Pharmaceuticals is a developer, manufacturer, and marketer of top-quality prescription pharmaceuticals. In two facilities with combined manufacturing, packaging, and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder, and oral solid dose products, including those requiring containment. ANI also performs contract manufacturing for some of the largest and most respected pharmaceutical companies in the world. ANI Pharmaceuticals was formed in 2001 and is based in Baudette, Minnesota.

Search 205,401 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 59 of 84
Sector (Life Science) 28 of 43
Type (PIPE) 1 of 1
State (Minnesota) 3 of 3
Country (United States) 54 of 69
Year (2021) 3 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-04 Bioventus

Durham, North Carolina, United States

Bioventus provides clinical and cost-effective therapies and diagnostics to help patients regain active lifestyles. The company's innovative products include bone stimulation devices and osteoarthritis joint fluid therapies. Bioventus was incorporated in 2011 and is based in Durham, North Carolina.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-18 Magritek

Wellington, New Zealand

Magritek is a scientific instrument company specializing in compact, portable, and benchtop NMR instruments offering the highest resolution and sensitivity performance of any benchtop instrument available today. Magritek was founded in 2004 and is based in Wellington, New Zealand.

Buy -
Mergr

Product

Company

Legal